RxDoctor Payments Data

Jay Lustbader

Ophthalmology · Washington, DCNPI 1720088545

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for ophthalmology clinicians in DC, where the typical reported total is $953.

$455in general payments, 2019–2025

Across 14 payments — averaging $32.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$104
  • Alcon$95
  • Amgen$85
  • Johnson & Johnson Surgical Vision, Inc.$65
  • Glaukos Corporation$39
  • Biotissue Holdings Inc.$25
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$455100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$455 in reported general payments places this provider in the 35th percentile of 74 ophthalmology providers in District of Columbia.

See all ophthalmology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$171,634
Medicare patients
431
Services billed
965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine27$25,821
XiidraLifitegrast16$17,299
Cyclosporine47$12,437
Loteprednol Etabonate22$4,075
Prednisolone Acetate55$3,013
Travoprost11$1,999
Bromfenac Sodium12$1,148
MoxifloxacinMoxifloxacin Hcl44$1,034
Ketorolac Tromethamine23$820
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat15$618
Atropine Sulfate13$472
Latanoprost26$312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$23$17,29916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 74 ophthalmology providers in District of Columbia.

Other ophthalmology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →